作者@article {Jack591 = {C。r·杰克,jr .)和m . m . Shiung和j·l·冈特和p c O {\ textquoteright} Brien s d . Weigand和d s Knopman b.f. Boeve和r . j . Ivnik和g·e·史密斯和Cha r·h·e . g . Tangalos r·c·彼得森}title ={比较不同MRI脑萎缩速率的措施在AD进展与临床疾病},体积={62}={4},页面= {591 - 600}= {2004},doi = {wnl.0000110315.26026 10.1212/01.。出版商EF} = {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:关联不同的测量方法的脑萎缩率从串行MRI与相应的临床变化在正常老年人,首页轻度认知障碍(MCI)患者和可能的阿尔茨海默病(AD)患者。方法:一百六十受试者招募从梅奥诊所{\ textquoteright}年代老年痴呆症研究中心和{\ textquoteright}年代老年痴呆症病人注册研究。在基线,55受试者认知正常,41 MCI满足标准,64遇到标准广告。每个主题的大脑进行了核磁共振检查时的基线临床评估,然后再在后续临床评估,1到5年。四种结构的年度变化体积测量从串行MRI研究:海马体,内嗅皮层,整个大脑和心室。利率的变化对一些认知测试/等级量表也被评估。受试者分为正常或MCI在基线可以保持稳定或转换为一个低组。广告对象被一分为二为慢速与快速不寻常。结果:四人萎缩发病率更高正常受试者转化为MCI或广告比在那些保持稳定,在MCI受试者转化为广告比在那些保持稳定,和更大的快比慢广告不寻常。 In general, atrophy on MRI was detected more consistently than decline on specific cognitive tests/rating scales. With one exception, no differences were found among the four MRI rate measures in the strength of the correlation with clinical deterioration at different stages of the disease. Conclusions: These data support the use of rates of change from serial MRI studies in addition to standard clinical/psychometric measures as surrogate markers of disease progression in AD. Estimated sample sizes required to power a therapeutic trial in MCI were an order of magnitude less for MRI than for change measures based on cognitive tests/rating scales.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/62/4/591}, eprint = {//www.ez-admanager.com/content/62/4/591.full.pdf}, journal = {Neurology} }